← 返回

EASIX 在 CAR-T 细胞治疗中未能在乳酸脱氢酶和 ECOG 体能状态之外增加预后价值:一项 GETH-TC 研究

英文原题:EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study.

查看英文原题

EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study.

PubMed 2025/10/25(内容时间) Transplant Cell Ther Q1 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

内皮激活和应激指数(EASIX)已被提出作为接受嵌合抗原受体(CAR)T细胞治疗患者中内皮并发症(如细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS))的预测指标。

然而,其在商业性抗CD19 CAR-T 细胞治疗后长期生存中的预后作用仍不确定。评估EASIX在预测接受CAR-T 细胞治疗患者生存结局和毒性方面的预后价值,并将其性能与常用临床生物标志物进行比较。这项回顾性多中心研究纳入126例在西班牙多个中心接受商业性CAR-T 细胞产品治疗的侵袭性B细胞淋巴瘤患者。EASIX-d0在CAR-T 输注前计算(EASIX-d0)。Cox比例风险模型评估与总生存期(OS)和无进展生存期(PFS)的关联,而逻辑回归用于毒性结局。受试者工作特征(ROC)分析比较EASIX-d0与LDH的预测性能。还评估了LDH-ECOG PS状态联合风险模型。较高的EASIX-d0值与较差的OS(HR:1.52,P < .001)和PFS(HR:1.30,P < .001)相关。EASIX-d0最高四分位组患者的OS(HR:4.40,P = .002)和PFS(HR:2.50,P = .03)显著更差。

然而,EASIX-d0与单独LDH在OS(AUC 71.6% vs 71.3%,P = .935)或PFS(68.5% vs 66.6%,P = .618)方面的预测性能无差异。与EASIX-d0相比,LDH-ECOG联合模型识别出3个风险组,对OS和PFS的区分能力更优。EASIX-d0与ICANS 2至4级和3至4级相关(OR 1.66,P = .001;OR 2.10,P = .001),但与 CRS 或非复发死亡率无关。虽然 EASIX-d0 可预测 CAR-T 细胞接受者的生存和 ICANS,但其预测能力在很大程度上由 LDH 驱动。它并不优于更易获取的标志物,如 LDH 和 ECOG PS。尽管近期研究提示 EASIX 与总生存期之间存在关联,但我们的结果强调,在真实世界队列中,LDH 和 ECOG 体能状态等更简单的参数可能提供同等或更优的预测能力。

展开英文摘要原文

The Endothelial Activation and Stress Index (EASIX) has been proposed as a predictor of endothelial complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients undergoing chimeric antigen receptor (CAR) T-cell therapy.

However, its prognostic role for long-term survival after commercial anti-CD19 CAR T-cell therapy remains uncertain. To evaluate the prognostic value of EASIX in predicting survival outcomes and toxicity in patients treated with CAR T-cell therapy, and to compare its performance with commonly available clinical biomarkers. This retrospective multicenter study included 126 patients with aggressive B-cell lymphomas treated with commercially available CAR T-cell products across multiple centers in Spain. EASIX-d0 was calculated prior to CAR-T infusion (EASIX-d0).

Cox proportional hazards models assessed associations with overall survival (OS) and progression-free survival (PFS), while logistic regression was used for toxicity outcomes. Receiver operating characteristic (ROC) analysis compared the predictive performance of EASIX-d0 versus LDH.

A combined LDH-ECOG PS status risk model was also evaluated. Higher EASIX-d0 values were associated with inferior OS (HR: 1. 52, P < . 001) and PFS (HR: 1. 30, P < . 001). Patients in the highest EASIX-d0 quartile showed significantly worse OS (HR: 4. 40, P = . 002) and PFS (HR: 2. 50, P = . 03).

However, predictive performance did not differ between EASIX-d0 and LDH alone for OS (AUC 71. 6% vs 71. 3%, P = . 935) or PFS (68. 5% vs 66. 6%, P = . 618). A combined LDH-ECOG model identified 3 risk groups with superior discrimination of OS and PFS compared to EASIX-d0. EASIX-d0 was associated with ICANS grades 2 to 4 and 3 to 4 (OR 1. 66, P = . 001; OR 2. 10, P = . 001), but showed no association with CRS or nonrelapse mortality.

While EASIX-d0 predicts survival and ICANS in CAR T-cell recipients, however its predictive capacity was largely driven by LDH. it does not outperform more accessible markers such as LDH and ECOG PS. While recent studies suggested associations between EASIX and overall survival, our results highlight that simpler parameters such as LDH and ECOG Performance Status may provide equal or superior predictive power in real-world cohorts.

论文信息

作者
Peña M、Martinez DF、López-Corral L、Martín-López AÁ、Sanchez-Salinas M、Benzaquén A、Hernani R、Sanz J
单位
Hematology Department, Hospital Duran i Reynals-Institut Catal&#xe0; d'Oncologia-Hospitalet, Barcelona, Spain; Institut d'Investigaci&#xf3; biom&#xe8;dica de Bellvitge (IDIBELL), Barcelona, Spain. Electronic address: mpena@iconcologia.net.Spain
文献类型
多中心研究
期刊
Transplantation and cellular therapy2026 Feb
原文标识
PubMed 41236021 · DOI 10.1016/j.jtct.2025.10.017